Goleta-based biotech Serimmune appoints new CEO
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Serimmune issues $1.4 million in promissory notes
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Winners of the 2018 Central Coast Innovation Awards announced
The Pacific Coast Business Times is pleased to announce our 2018 winners of the Central Coast Innovation Awards. This annual special section, now in its third year, published with the Feb. 23 print edition. A two-part event on Thursday, March 15 begins with Startup Village and concludes with an evening awards reception for the honorees Read More →
SerImmune gets $8 million in financing from Illumina Ventures
Santa Barbara immunotherapy and diagnostic company SerImmune received $8 million in financing from San Francisco-based Illumina Ventures to expand its immune mapping platform and database. Illumina invests primarily in early-stage companies researching genomics, life science and health care. A subsidiary of pharmaceutical giant Merck also participated in the financing round, alongside other undisclosed investors. Mapping Read More →
Diagnostic companies aim to disrupt medical industry
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Getting a grip on diabetes: Aptitude device gets fast track status for clinical trials
Aptitude creates a special type of molecule called an aptamer, which it is using to develop a first-of-its-kind hand-held device that measures insulin concentrations in real-time and can diagnose pre-diabetes. The government’s interest in furthering such research is unsurprising as diabetes affects more than 9 percent of Americans.
